We all know that small, under-financed biotech can take years before they hit with one drug. But as Grip points out, "As a value investor, I'm looking for which portions of that report are not true." And, "Culper readily outlines it's their OPINION..."
This is just OPINION. Yes, this is also the current state but the CEO is not the molecule.
I'm not really understanding your position. You say as a value investor, what? A value investor would not invest in this company, given what you have laid out. As a value investor, you already know what is not true. So why waste your time here?
Sub $1.41 price
No approvals
No revenue
Funding almost out if the Fife shelf isn't allowed
Shareholder lawsuits that cost MILLIONS of dollars
Arbitration loss for lying about firing Pestell
CD10 and CD12 FAILED! The 82% is a subset of a subset. Cytodyn's SEC filings say it failed! They didn't meet the endpoints. PERIOD, hard stop.
As a value investor, I'm looking for which portions of that report are not true.
Culper readily outlines it's their OPINION based on the science, trials, assertions and failures. They're totally in the clear.
Now, a CEO spewing triple-digit stock projections while selling $10+ million in stock and the CFO selling $5-6M in stock during the runup might get the SEC and DOJ's attention...oh wait! Subpoena's have been issued to a two-time felon who declared personally bankruptcy twice. Is that the moral fiber and fiscal responsibility that a mechanical engineer should possess to run a bio company?
Market Data 
Markets 
AI
